Back to top

Analyst Blog

Mindray Medical International Limited (MR - Analyst Report), a leading Chinese medical device manufacturer, recently revealed certain unaudited early results for 2011. In addition, the company issued net sales guidance for 2012.

Mindray forecasts net revenues of about $878 million for the year ended December 31, 2011, up approximately 24.7%. The company anticipates adjusted net income to rise at least 10% year over year. Adjusted net income assumes a corporate income tax rate of 15% for the Shenzhen unit.   

Mindray was pleased to generate robust double-digit sales growth for fiscal 2011 despite the difficult global macro economic situation. Sales were buoyant in China on account of positive hospital and government spending patterns. Emerging markets (outside China) were a key growth driver and the company captured market share in developed nations.

The company released as many as 13 new products in 2011. It engaged in 4 new acquisitions during the year.

For 2012, Mindray expects its sales to increase not less than 18% year of year. The company will provide a detailed guidance for 2012 with its 2011 financial results.

Mindray is a bellwether in the Chinese MedTech industry with a solid international presence. A key distinction with domestic competitors is that the majority of Mindray’s products have CE Mark and/or Food and Drug Administration (“FDA”) clearance.

Mindray maintains a decent product pipeline and brings out several new products each year. New products contribute in a major way to its revenues.

The company has entered the premium segment globally, where its competitive advantage is still unclear. Also, on the negative side, health care reform, in China and the U.S., may reduce demand for Mindray’s products. Competition is fierce and leads to price erosion over time.

Mindray’s competitors, in different niche segments, include General Electric (GE - Analyst Report), Philips (PHG - Analyst Report) and Siemens . Our Neutral recommendation is supported by a short-term Zacks #3 Rank (Hold).

Please login to Zacks.com or register to post a comment.

New to Zacks?

Start Here

Zacks Investment Research

Close

Are you a new Zacks Member or a visitor to Zacks.com?

Top Zacks Features

My Portfolio Tracker

Is it Time to Sell?

One of the most important steps you can take today is to set up your portfolio tracker on Zacks.com. Once you do, you'll be notified of major events affecting your stocks and/or funds with daily email alerts.

More Zacks Resources

Zacks Rank Home - Evaluate your stocks and use the Zacks Rank to eliminate the losers and keep the winners.

Mutual Fund Rank Home - Evaluate your funds with the Mutual Fund Rank for both your personal and retirement funds.

Stock/Mutual Fund Screening - Find better stocks and mutual funds. The ones most likely to beat the market and provide a positive return.

My Portfolio - Track your Portfolio and find out where your stocks/mutual funds stack up with the Zacks Rank.

Zacks #1 Rank Top Movers for Zacks #1 Rank Top Movers

Company Symbol Price %Chg
ERBA DIAGNO… ERB 3.80 +7.04%
TRAVELCENTE… TA 11.84 +6.38%
BANCO DO BR… BDORY 14.74 +5.66%
AIR INDUSTR… AIRI 9.99 +4.15%
EQT MIDSTRM… EQM 98.14 +3.38%